Stéphane Bancel, Moderna CEO (Lenin Nolly/NurPhoto via AP Images)
September 12, 2024 06:00 AM EDTUpdated 09:33 AM
R&D

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Andrew Dunn

Senior Biopharma Correspondent

Stéphane Ban­cel has re­lent­ed to Wall Street’s de­sire for cost-cut­ting and rein­ing in Mod­er­na’s pipeline.

To kick off its an­nu­al R&D day in New York …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times